Evaluation of statin users in cardiology and oncology
Session
Pharmaceutical and Natural Sciences
Description
Administration of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, also known as statins, to ambulatory and hospital patients is linked with a decreased incidence of long-term adverse cardiovascular events such myocardial infarction, stroke, atrial fibrillation, and renal failure. However, increasing clinical evidence suggests that statins, independent of their effects on serum cholesterol levels, may also play a potential role in the prevention and treatment of cancer. In particular, it has been demonstrated in multiple studies that statins offer a number of advantageous anti-cancer effects, such as a reduction in metastasis, angiogenesis, and tumor development. However other research support as risk factor for cancer incidence. Our main goal was to assess statin users on oncology using their identification and use of different types of cancer and statin identification in cancer patients, duration of their use, their impact on cancer incidence, and action their anticancer drugs to the most prevalent cancers for the time of monitoring.
The research is based on interviewing patients at the Clinic of Oncology at University Clinical Center of Kosovo. with a questionnaire where we interviewed a total of 196 patients, 176 of whom were outpatients and 20 patients were hospitalized. Where then the collected data from patients are transferred to a database created in the Excel program where from there all the data are presented in the form of tables and graphs. Out of 196 patients divided into 4 different groups, with dominant breast cancer with 66 patients, then cervical cancer with 53 patients, lung cancer with 40 patients and 37 patients with prostate cancer. Out of the 196 patients, 53 of them have been statin users. All results are presented in tabular form and graphs.
By five hypotheses derived from our results as well as comparing our results with other scientific studies made by experts in this field, we found matching and contradictions with other studies.
From our results as well as from many other researched results we can state that statins can be an additional drug for breast, cervical and lung cancer but on the other hand they have not shown positive results in prostate cancer patients. However, this kind of study does not yet have a concrete conclusion.
Keywords:
Statins, HMG-CoA inhibitors, cancer, breast cancer, prostate cancer, lung cancer, cervical cancer.
Proceedings Editor
Edmond Hajrizi
ISBN
978-9951-550-50-5
Location
UBT Kampus, Lipjan
Start Date
29-10-2022 12:00 AM
End Date
30-10-2022 12:00 AM
DOI
10.33107/ubt-ic.2022.94
Recommended Citation
Tahiri, Diellza; Daci, Armond; and Ibishi, Endrit, "Evaluation of statin users in cardiology and oncology" (2022). UBT International Conference. 94.
https://knowledgecenter.ubt-uni.net/conference/2022/all-events/94
Evaluation of statin users in cardiology and oncology
UBT Kampus, Lipjan
Administration of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, also known as statins, to ambulatory and hospital patients is linked with a decreased incidence of long-term adverse cardiovascular events such myocardial infarction, stroke, atrial fibrillation, and renal failure. However, increasing clinical evidence suggests that statins, independent of their effects on serum cholesterol levels, may also play a potential role in the prevention and treatment of cancer. In particular, it has been demonstrated in multiple studies that statins offer a number of advantageous anti-cancer effects, such as a reduction in metastasis, angiogenesis, and tumor development. However other research support as risk factor for cancer incidence. Our main goal was to assess statin users on oncology using their identification and use of different types of cancer and statin identification in cancer patients, duration of their use, their impact on cancer incidence, and action their anticancer drugs to the most prevalent cancers for the time of monitoring.
The research is based on interviewing patients at the Clinic of Oncology at University Clinical Center of Kosovo. with a questionnaire where we interviewed a total of 196 patients, 176 of whom were outpatients and 20 patients were hospitalized. Where then the collected data from patients are transferred to a database created in the Excel program where from there all the data are presented in the form of tables and graphs. Out of 196 patients divided into 4 different groups, with dominant breast cancer with 66 patients, then cervical cancer with 53 patients, lung cancer with 40 patients and 37 patients with prostate cancer. Out of the 196 patients, 53 of them have been statin users. All results are presented in tabular form and graphs.
By five hypotheses derived from our results as well as comparing our results with other scientific studies made by experts in this field, we found matching and contradictions with other studies.
From our results as well as from many other researched results we can state that statins can be an additional drug for breast, cervical and lung cancer but on the other hand they have not shown positive results in prostate cancer patients. However, this kind of study does not yet have a concrete conclusion.